The strong association between cardiometabolic disease and CV health provides a compelling reason for health care providers to work together to reduce cardiometabolic risk factors through early assessment and targeted interventions. This  program will provide an in-depth review and analysis of current state-of-the-art practices and emerging therapies in CVD risk reduction.

After completing this activity, participants will be able to:

• Reduce cardiovascular risk through optimal management of dyslipidemia, hypertension, diabetes, and obesity.
• Recognize the associative risk of cardiovascular disease with elevated LP(a).
• Assess the efficacy of a small interfering RNA (siRNA)  in the management of HTN
• Appraise present and potential future therapeutic options for modification of CVD risk factors